Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
- Popular podcaster and influencer Joe Rogan has been accused of cashing in on brain health supplement2024-05-22
China to hold first space cooperation forum with LatAm, Caribbean countries
China will hold the first space cooperation forum with Latin American and the Caribbean countries du2024-05-22- MADRID (AP) — Rafael Nadal’s body withstood its toughest test yet at the Madrid Open as he needed th2024-05-22
Parents of Michigan high school shooter sentenced 10
The screenshot taken from the streaming of ABC7 New York shows Jennifer Crumbley, whose then 15-year2024-05-22Lynn Williams breaks NWSL goal
Lynn Williams scored her 79th league goal, becoming the National Women’s Soccer League all-time scor2024-05-22Chinese ballet to illuminate Dutch stadium
The National Ballet of China (NBC) is set to captivate audiences in the northern Dutch province of F2024-05-22
atest comment